NASDAQ
3.87USD
+0.04 (+1.18%)
We have scored 11 news catalysts on Larimar Therapeutics, Inc. (LRMR) over the past 12 months. The biggest single-day move next to one of them came Feb 25, 2026, when LRMR closed +61.2%: “Laminar Therapeutics Stock Is Popping Today: What's Going On?”. Coverage across the window leans negative (average ticker sentiment −0.17). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
401.5M
P/E
—
EPS
—
Beta
0.75
52W range
2.715-6.42
Day range
3.71–3.90
Open
3.80
Prev close
3.82
Volume
2.7M
Avg volume
1.8M
Dividend
0.00
IPO
2014-06-19
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Larimar Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for LRMR: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
